Siqing Fu

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors

  Journal for ImmunoTherapy of Cancer · 2026-06-01

• Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity

  The Oncologist · 2026-03-06

• Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

  The Oncologist · 2025-12-11

• PAFF: a progression-aware fusion framework on pseudo-paired data for prognostic prediction in hepatocellular carcinoma

  2025-12-04

• Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

  2025-11-25

• Supplementary Tables S1-S4 from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

  2025-11-25

• Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

  2025-11-25

• Table S1, Table S2, Table S3 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

  2025-11-25

• Supplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

  2025-11-25

• An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma

  Journal of Experimental & Clinical Cancer Research · 2025-11-14 · 2 citations

• Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations

  ESMO Open · 2025-11-13

• 672 Immune activation with plinabulin promotes monocyte-macrophage responses combining radiation with immune checkpoint blockade (ICB) in ICB-relapsed/refractory tumors

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Dihydroorotate dehydrogenase inhibition activates STING pathway and pyroptosis to enhance NK cell-dependent tumor immunotherapy

  Molecular Biomedicine · 2025-10-27 · 3 citations

• Abstract C063: Discrepancies Between Calculated and Actual Creatinine Clearance: A Phase 1 Trial Unit Experience

  Molecular Cancer Therapeutics · 2025-10-22

• The role and diagnostic progress of exosomes in childhood allergic asthma: A review

  Medicine · 2025-10-10

• Data from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

  2025-09-15

• Supplementary File S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors

  2025-09-15

• Supplementary Table S4 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors

  2025-09-15

• Supplementary Table S1 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

  2025-09-15

• Figure 1 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

  2025-09-15